Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (339)	10/7/2004 7:42:12 PM
From: tuck	Respond to of 416

So is ID Biomedical, but they can't yet say this about FluNsure: >>GAITHERSBURG, Md., Oct. 7 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI - News) announced today that FluMist® (Influenza Virus Vaccine Live, Intranasal) is now available to the general public in doctors' offices, hospitals and some pharmacies throughout the United States. MedImmune will provide one million to two million doses of FluMist for the 2004-2005 influenza season. As stated in the October 5, 2004 Morbidity and Mortality Weekly Report distributed by the U.S. Centers for Disease Control of prevention (CDC): "Intranasally administered, live, attenuated influenza vaccine, if available, should be encouraged for healthy persons who are aged 5-49 years and are not pregnant, including health-care workers (except those who care for severely immunocompromised patients in special care units) and persons caring for children aged <6 months." FluMist will be available this flu season for $16.00 wholesale per non- returnable dose or $23.50 wholesale per returnable dose -- reflecting a price drop of 50 percent or more compared to the 2003-2004 season. For more information about FluMist, visit flumist.com. Physicians, pharmacists and other healthcare professionals interested in ordering FluMist may call (877) FLUMIST. About FluMist FluMist is the first live, attenuated influenza vaccine indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age. There are risks associated with all vaccines, including FluMist. FluMist does not protect 100-percent of individuals vaccinated, or may not protect against viral strains not represented in the vaccine. FluMist is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-Barre syndrome; and in individuals with known or suspected immune deficiency. The safety and efficacy of FluMist have not been established in pregnant women or for patients with chronic underlying medical conditions, including asthma or reactive airways disease; the vaccine should not be administered to these patients. See Prescribing Information for indications and usage, dosage and administration and safety information.<< snip Cheers, Tuck